このページは機械翻訳されています。他のページは英語で表示される場合があります。
View in English
EGFR変異性NSCLCの患者で,第3世代のEGFR- TKIsで治療された前期対後期の生存結果
- Guangchuan Deng 1, Yuanliang Zhou 2,3, Zhimin Wang 4, Jing Fan 2,3, Chenran Zhao 2,3, Jianbin Li 5,6, Zhenxiang Li 7
- Guangchuan Deng 1, Yuanliang Zhou 2,3, Zhimin Wang 4
- 1Department of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Tianwen Avenue No. 288, Nan'an District, Chongqing, 400010, China.
- 2Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan City, 250117, China.
- 3Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan City, 250117, Shandong Province, China.
- 4Department of Oncology, Yishui County People's Hospital, Linyi City, 276400, Shandong Province, China.
- 5Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan City, 250117, China. lijianbin@msn.com.
- 6Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan City, 250117, Shandong Province, China. lijianbin@msn.com.
- 7Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan City, 250117, China. lizx0108@163.com.
- 0Department of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Tianwen Avenue No. 288, Nan'an District, Chongqing, 400010, China.
関連する実験動画
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.

